GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales

London-based GSK is preparing to roll out its RSV vaccine in the U.S. and European Union this fall.

from Health and Science https://ift.tt/yPA6clB
https://ift.tt/hRSXa1N
https://ift.tt/baem2xB